Early oral administration of alendronate in elderly Schatzker type Ⅱ tibial plateau fracture is beneficial to postoperative knee function recovery

doi:10.3877/cma.j.issn.1674-134X.2019.02.019

Abstract

Abstract:

Objective

To study the relationship between the timing of anti-osteoporosis treatment and knee function recovery after surgery for elderly Schatzker type Ⅱ tibial plateau fractures.

Methods

Prospective analysis of the elderly patients with Schatzker type Ⅱ fractures of the unilateral tibial plateau who underwent surgery in Gansu Provincial People’s Hospital from January 2017 to January 2018. According to the timing of oral administration of alendronate against osteoporosis, it was divided into one week after operation group and three months after operation group. Comparison of knee injury and osteoarthritis outcome score (KOOS) in two groups after discontinuation of alendronate for three months were taken.

Results

A total of 33 patients were enrolled in the study. Nineteen patients received oral alendronate within one week after surgery and 14 patients started oral alendronate three months after surgery. The median of KOOS overall scores in the two groups were 87 (82, 89), 63 (56, 66), respectively, and Mann-Whitney U test P<0.05 indicating that the difference of knee function recovery was statistically significant.

Conclusion

In the elderly Schatzker type Ⅱ tibial plateau fracture, the knee joint function recovered after oral administration of alendronate for within one week postoperative is better than that of three months after surgery.

Key words: Tibial fractures, Intra-articular fractures, Osteoporotic fractures, Drug therapy, Aged

Zhan Wang, Yuxin Song, Yaowen Qian. Early oral administration of alendronate in elderly Schatzker type Ⅱ tibial plateau fracture is beneficial to postoperative knee function recovery[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2019, 13(02): 242-244,247.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2019.02.019

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2019/V13/I02/242

Figures/Tables 1

References 26

[1]	徐晓，王雷涛，贾兆锋，等．胫骨平台骨折诊治的研究进展[J]．生物骨科材料与临床研究，2017，14(1):69-72, 76.
[2]	顾梦臻，唐献忠，于荣华，等.2种钢板内固定治疗复杂胫骨平台骨折对患肢负重时间的影响[J]．中国骨与关节损伤杂志，2016，31(4):430-432.
[3]	Van Dreumel RL, Van Wunnik BP, Janssen L, et al. Mid- to long-term functional outcome after open reduction and internal fixation of tibial plateau fractures[J]. Injury, 2015, 46(8):1608-1612.
[4]	Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture[J]. J Bone Miner Res, 2009, 24(7):1308-1313.
[5]	Cecilia D, Jodar E, Fernandez C, et al. Effect of alendronate in elderly patients after low trauma hip fracture repair[J]. Osteoporosis Int, 2009, 20(6):903-910.
[6]	Colon-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing[J]. Osteoporosis Int, 2011, 22(8):2329-2336.
[7]	Gong HS, Lee JO, Huh JK, et al. Comparison of depressive symptoms during the early recovery period in patients with a distal radius fracture treated by volar plating and cast immobilisation[J]. Injury, 2011, 42(11):1266-1270.
[8]	Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy[J]. J Hand Surg Am, 2009, 34A(4):595-602.
[9]	王伟．两种方法治疗Schatzker Ⅵ型胫骨平台骨折疗效比较[J]．临床骨科杂志，2015，18(3):342-345.
[10]	夏维波．双膦酸盐在骨质疏松症的应用：回眸中国20年[J]．中华骨质疏松和骨矿盐疾病杂志，2018，11(6):521-531.
[11]	孟迅吾，朱汉民，刘建立，等．阿伦膦酸钠防治原发性骨质疏松症[J]．中华内分泌代谢杂志，1998，14(5):18-21.
[12]	Leung JY, Ho AY, Ip TP, et al. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study[J]. Bone, 2005, 36(2):358-364.
[13]	Hwang JS, Chin LS, Chen JF, et al. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis[J]. J Bone Miner Metab, 2011, 29(3):328-333.
[14]	Li M, Zhang ZL, Liao EY, et al. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis[J]. Menopause, 2013, 20(1):72-78.
[15]	Huang SS, Lin H, Zhu XF, et al. Zoledronic acid increases bone mineral density and improves health-related quality of Life over two years of treatment in Chinese women with postmenopausal osteoporosis[J]. Endokrynol Pol, 2014, 65(2):96-104.
[16]	Liang BC, Shi ZY, Wang B, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in East China subjects with newly diagnosed osteoporosis: a 24-month clinical study[J]. Orthop Surg, 2017, 9(1):103-109.
[17]	Zhang ZL, Liao EY, Xia WB, et al. Alendronate sodium/vitamin D-3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension[J]. Osteoporosis Int, 2015, 26(9):2365-2374.
[18]	Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis[J]. Mayo Clin Proc, 2007, 82(12):1493-1501.
[19]	Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis[J]. Osteoporosis Int, 2006, 17(11):1645-1652.
[20]	Goldhahn J, Feron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper[J]. Calcif Tissue Int, 2012, 90(5):343-353.
[21]	邱贵兴，裴福兴，胡侦明，等．中国骨质疏松性骨折诊疗指南(全文)(骨质疏松性骨折诊断及治疗原则)[J/CD]．中华关节外科杂志(电子版)，2015，9(6):795-798.
[22]	白波，吴增辉，刘康妍，等． "中国骨质疏松性骨折诊疗指南"专家研讨会议纪要[J/CD]．中华关节外科杂志(电子版)，2015, 10(6):799.
[23]	中华医学会骨质疏松和骨矿盐疾病分会．原发性骨质疏松症诊疗指南(2017)[J]．中华骨质疏松和骨矿盐疾病杂志，2017，10(5):413-444.
[24]	Amanat N, Mcdonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair[J]. J Bone Miner Res, 2007, 22(6):867-876.
[25]	Moroni A, Faldini C, Hoang-Kim A, et al. Alendronate improves screw fixation in osteoporotic bone[J]. J Bone Joint Surg Am, 2007, 89(1):96-101.
[26]	Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures[J]. Arch Intern Med, 2004, 164(10):1108-1112.

开始抗骨质疏松治疗时机	例数	性别(男/女)	年龄[岁，(±s)]
术后1周内	19	13/6	72±5
术后3个月后	14	10/4	70±5
统计值	?	χ²＝3.295	t＝1.773
P值	?	>0.05	>0.05

开始抗骨质疏松治疗时机	例数	性别(男/女)	年龄[岁，(±s)]
术后1周内	19	13/6	72±5
术后3个月后	14	10/4	70±5
统计值	?	χ²＝3.295	t＝1.773
P值	?	>0.05	>0.05

Please choose a citation manager

Content to export